3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Triple Negative Breast Neoplasms
2
Recurrence
1
Neoplasms
1
Multiple Myeloma
1
Lymphoma, Mantle-Cell
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma, B-Cell
1
Lymphoma
1
Locally Advanced (Inoperable) or Metastatic Breast Cancer
1
Hematologic Neoplasms
1
Carcinosarcoma
1
Carcinoma, Endometrioid
1
Breast Neoplasms
1
Advanced Solid Malignancy,
1
Interventions
Nivolumab
11
Ipilimumab
6
linrodostat
4
relatlimab
3
Pemetrexed
2
tislelizumab
1
regorafenib
1
ralimetinib
1
p38 Mitogen-Activated Protein Kinases
1
mirdametinib
1
gedatolisib
1
figitumumab
1
efatutazone
1
abemaciclib
1
Vorinostat
1
Tetanus Toxoid
1
Tamoxifen
1
Sunitinib
1
Ranitidine
1
Midazolam
1
LY2603618
1
LY2584702
1
Irinotecan
1
Gemcitabine
1
Fulvestrant
1
Dasatinib
1
Cyclophosphamide
1
Crizotinib
1
Cetuximab
1
Carboplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Has results
×
Advanced Cancer
×
capivasertib
×
Clear all
No trials found.